LABT (LABT)
3.41
+1.55 (83.33%)
Upcoming Events
Latest Headlines
Lakewood-Amedex shares resistance data for antibiotic candidate Nu-3
July 22, 2026 8:03 AM - StreetInsider
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
July 22, 2026 8:02 AM - PR NewsWire
Form 8-K Lakewood-Amedex Biothera For: Jul 15
July 15, 2026 4:16 PM - SEC Filing
Lakewood-Amedex reports preclinical safety data for Nu-3 gel trial
July 15, 2026 8:02 AM - StreetInsider
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
July 15, 2026 8:02 AM - PR NewsWire
Lakewood-Amedex backs PASTEUR Act, plans Phase 2 trial for Nu-3
July 7, 2026 8:03 AM - StreetInsider
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
July 7, 2026 8:02 AM - PR NewsWire
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
June 26, 2026 8:35 AM - StreetInsider
Lakewood-Amedex names USC professor to chair diabetic foot ulcer trial
June 25, 2026 8:02 AM - StreetInsider
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
June 25, 2026 8:02 AM - PR NewsWire
Form SCHEDULE 13G Lakewood-Amedex Biothera Filed by: HPW Investments Holding Ltd.
June 23, 2026 11:10 AM - SEC Filing
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
June 23, 2026 8:35 AM - Globe NewsWire
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
June 23, 2026 8:35 AM - StreetInsider
Form 424B3 Lakewood-Amedex Biothera
June 22, 2026 4:12 PM - SEC Filing
Form 424B3 Lakewood-Amedex Biothera
June 22, 2026 4:11 PM - SEC Filing
Lakewood-Amedex receives Australian patent for antimicrobial compounds
June 22, 2026 8:04 AM - StreetInsider
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
June 22, 2026 8:02 AM - PR NewsWire
Form 8-K Lakewood-Amedex Biothera For: Jun 15
June 17, 2026 11:41 AM - SEC Filing
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
June 16, 2026 8:02 AM - PR NewsWire
Lakewood-Amedex secures patents in Australia and New Zealand for Nu-3
May 27, 2026 8:03 AM - StreetInsider
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
May 27, 2026 8:02 AM - PR NewsWire
Form 424B3 Lakewood-Amedex Biothera
May 26, 2026 4:16 PM - SEC Filing
Form 424B3 Lakewood-Amedex Biothera
May 26, 2026 4:15 PM - SEC Filing
Form 10-Q Lakewood-Amedex Biothera For: Mar 31
May 22, 2026 4:55 PM - SEC Filing
Lakewood-Amedex completes manufacturing steps for Nu-3 diabetes drug trial
May 18, 2026 8:02 AM - StreetInsider
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
May 18, 2026 8:02 AM - PR NewsWire
Form 424B4 Lakewood-Amedex Biothera
May 14, 2026 4:19 PM - SEC Filing
Form EFFECT Lakewood-Amedex Biothera
May 14, 2026 6:09 AM - SEC Filing
Lakewood-Amedex partners with PERI for Nu-3 phase 2 trial
May 12, 2026 8:02 AM - StreetInsider
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3
May 12, 2026 8:02 AM - PR NewsWire
Form 4 Lakewood-Amedex Biothera For: Apr 24 Filed by: Tucker Joseph Edward
May 6, 2026 6:20 PM - SEC Filing
Form 3 Lakewood-Amedex Biothera For: Apr 24 Filed by: Tucker Joseph Edward
May 6, 2026 6:19 PM - SEC Filing
Form 3 Lakewood-Amedex Biothera For: Apr 17 Filed by: DeRoma Leonard James
May 1, 2026 6:32 PM - SEC Filing
Form 3 Lakewood-Amedex Biothera For: Apr 17 Filed by: Balzer Thomas
May 1, 2026 5:46 PM - SEC Filing
Form 3 Lakewood-Amedex Biothera For: Apr 17 Filed by: Cooper Kelvin
May 1, 2026 5:45 PM - SEC Filing
Form 3 Lakewood-Amedex Biothera For: Apr 17 Filed by: Ceccacci Peter
May 1, 2026 5:45 PM - SEC Filing
Form S-1 Lakewood-Amedex Biothera
May 1, 2026 4:06 PM - SEC Filing
Lakewood-Amedex reports low resistance development in antimicrobial tests
May 1, 2026 8:05 AM - StreetInsider
Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers
May 1, 2026 8:02 AM - PR NewsWire
Form 424B3 Lakewood-Amedex Biothera
April 30, 2026 4:27 PM - SEC Filing
Form 8-K Lakewood-Amedex Biothera For: Apr 24
April 28, 2026 4:16 PM - SEC Filing
Lakewood-Amedex names Joseph Tucker to board following Nasdaq listing
April 28, 2026 7:33 AM - StreetInsider
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
April 28, 2026 7:33 AM - PR NewsWire
Full Article List
